<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001781605</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001830214</issuerCik>
      <issuerName>Ginkgo Bioworks Holdings, Inc.</issuerName>
      <secFileNumber>001-40097</secFileNumber>
      <issuerAddress>
        <com:street1>27 DRYDOCK AVENUE</com:street1>
        <com:street2>8TH FLOOR</com:street2>
        <com:city>BOSTON</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02210</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>(877) 442-5362</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Novalis LifeSciences Investments I, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
        <relationshipToIssuer>Footnote #1 (See Remarks)</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Class A Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Cowen and Company, LLC</name>
        <address>
          <com:street1>599 Lexington Ave Floor 21</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10022</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>265000</noOfUnitsSold>
      <aggregateMarketValue>220029.50</aggregateMarketValue>
      <noOfUnitsOutstanding>1709063953</noOfUnitsOutstanding>
      <approxSaleDate>05/16/2024</approxSaleDate>
      <securitiesExchangeName>NYSE</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Class A Common Stock</securitiesClassTitle>
      <acquiredDate>09/17/2021</acquiredDate>
      <natureOfAcquisitionTransaction>SPAC/Business Combination</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Novalis LifeSciences Investments I, L.P.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>265000</amountOfSecuritiesAcquired>
      <paymentDate>09/17/2021</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Marijn E. Dekkers</name>
        <address>
          <com:street1>27 Drydock Avenue, 8th floor</com:street1>
          <com:city>Boston</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02210</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Ginkgo Bioworks Holdings, Inc - Class A</securitiesClassTitle>
      <saleDate>05/14/2024</saleDate>
      <amountOfSecuritiesSold>1727056</amountOfSecuritiesSold>
      <grossProceeds>1605120.56</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>(1) Novalis LifeSciences Investments I GP, LLC is the general partner (the General Partner) of Novalis LifeSciences Investment I, L.P. (the Fund). Marijn E. Dekkers is the Manager of the General Partner and has sole voting and Investment control over all of the shares of the Issuer held by the Fund. Marijn E. Dekkers is a member of the Board of Directors of the Issuer. The Fund is a less than ten percent stockholder of the issuer.</remarks>
    <noticeSignature>
      <noticeDate>05/16/2024</noticeDate>
      <signature>Marijn E. Dekkers</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
